Sharaf, Radwa http://orcid.org/0000-0002-5214-380X
Jin, Dexter X.
Grady, John
Napier, Christine
Ebot, Ericka http://orcid.org/0000-0001-7144-693X
Frampton, Garrett M. http://orcid.org/0000-0002-2361-2750
Albacker, Lee A.
Thomas, David M.
Montesion, Meagan http://orcid.org/0000-0001-9155-556X
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (GNT1195742, GNT1195742, GNT1195742)
Article History
Received: 17 May 2023
Accepted: 18 August 2023
First Online: 14 September 2023
Competing interests
: RS, DXJ, EE, GMF, LAA, and MM are employees of Foundation Medicine, Inc., a wholly owned subsidiary of Roche Holdings, Inc. and Roche Finance Ltd, and these employees have equity interest in an affiliate of these Roche entities. DT is the CEO of Omico, which provides national precision oncology services in Australia. DT has commercial and academic partnerships with multiple industry partners, including: Roche, Pfizer, Eisai, Astra Zeneca, Amgen, Abbvie, Eli Lilly, Beigene, Bayer, Illumina, Foundation Medicine, Microba, Merck, GMDx, Biotessellate, InterVenn. DT acts in a consultant capacity to the Health Futures Fund of Australian Unity, and the Maine Cancer Genome Initiative. All other authors don’t have conflicts of interest.